Polaris ADMET

Industry-contributed ADMET benchmarks on Polaris Hub (Novartis/AstraZeneca/Polaris SC curated endpoints).

Composite

88.4

Experimental validation

Prospective

Stages

Lead ID / ADMET

Modalities

small-molecule

Task types

regressionclassification

Size

endpoints: 12
molecules: 50,000

License

Polaris Community

First release

2023-10

Last updated

2025-04

Official site

→ project page

Leaderboard

→ leaderboard

Dataset

→ dataset

Code / GitHub

→ repository

HuggingFace

→ HF

Paper

Polaris: method comparison in drug discovery · Wognum C, Noutahi E, Hsu J, et al. · 2024 · paper · doi:N/A — working paper · 30 citations

Flags

none

Experts

Cas Wognum, Emmanuel Noutahi, Jonathan Hsu

Groups

Valence Labs (Recursion), Recursion Pharmaceuticals, Novartis BR / AIDD, AstraZeneca AIDD

Hosted by

Polaris Hub

Related benchmarks

TDC ADMET Group, MoleculeNet

Rubric (7-criterion)

rigor

coverage

maintenance

adoption

quality

accessibility

industry_relevance

Notes

Industry splits enforce blinded eval; highest industry relevance among ADMET benchmarks.

← Back to all benchmarks

Compare:

Open comparison →